RxDoctor Payments Data

Richard Kincaid, APRN

Family · Lebanon, TNNPI 1073742250

Payments from drug & device makers

$9,536in general payments, 2019–2025

Across 590 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • GSK$1K
  • AstraZeneca$1K
  • AbbVie$860
  • Amgen$467
  • Lilly USA, LLC$396
  • plus $3K from 46 others

What the payments were for

  • Food & beverage$9,536100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,536 in reported general payments places this provider in the 95th percentile of 6,706 family providers in Tennessee.

See all family providers in Tennessee

Medicare billing

Part B allowed, 2024
$66,260
Medicare patients
379
Services billed
19,002

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide43$71,515
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$39,094
JardianceEmpagliflozin17$24,097
EliquisApixaban16$21,145
JanuviaSitagliptin Phosphate16$16,308
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$11,285
MounjaroTirzepatide11$11,249
EntrestoSacubitril/Valsartan16$10,576
FarxigaDapagliflozin Propanediol12$9,715
TradjentaLinagliptin12$8,998
Tresiba Flextouch U-100Insulin Degludec17$8,151
LinzessLinaclotide12$7,843
Tresiba Flextouch U-200Insulin Degludec11$6,540
PaxlovidNirmatrelvir/Ritonavir39$4,216
Albuterol Sulfate HfaAlbuterol Sulfate110$3,800

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$2,004$71,51543 claims
GSKTrelegy Ellipta$1,250$39,09449 claims
Boehringer IngelheimJardiance, Tradjenta$366$33,09629 claims
PfizerEliquis, Paxlovid$68$25,36155 claims
MerckJanuvia$16$16,30816 claims
Lilly USA, LLCMounjaro$396$11,24911 claims
NovartisEntresto$114$10,57616 claims
AstraZenecaFarxiga$1,103$9,71512 claims
AbbVieLinzess, Synthroid$860$9,17440 claims
Sanofi-aventis U.S. LLCLantus$69$1,80026 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,706 family providers in Tennessee.

Other family in Lebanon

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →